Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE104 PK in Breast Milk of Healthy Lactating Women
NCT06659263Phase 1Completed
- Sponsor
- Reunion Neuroscience
- Start
- Nov 2024
- Primary completion
- May 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RE104 in postpartum depression (PPD), sponsored by Reunion Neuroscience. Primary endpoints: Area under the concentration-time curve from time zero to 24 hours post-dose, Area under the concentration-time curve from time zero to the time of the last quantifiable concentration and 7 more. Started Nov 2024; status: completed.
02
Drugs
RE104
03
Conditions
postpartum depression (PPD)
Beyond the preview
Go deeper on NCT06659263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06659263.